Lavinia Tan - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Lavinia Tan

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

Nature Communications|February 28, 2024

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATELavinia Tan, Chris Brown, Antony Mersiades, et al.

Cancer Cell|October 1, 2019

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in CancerMarian L Burr, Christina E Sparbier, Kah Lok Chan, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

Nature Communications|February 28, 2024

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATELavinia Tan, Chris Brown, Antony Mersiades, et al.

Cancer Cell|October 1, 2019

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in CancerMarian L Burr, Christina E Sparbier, Kah Lok Chan, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.

Pageof 3